Immunic (NASDAQ:IMUX) Now Covered by Analysts at Guggenheim

Guggenheim initiated coverage on shares of Immunic (NASDAQ:IMUX) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $7.00 price target on the stock.

A number of other equities research analysts also recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. raised Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. HC Wainwright dropped their price objective on Immunic from $8.00 to $5.00 and set a “buy” rating for the company in a report on Monday, March 2nd. Finally, D. Boral Capital cut their target price on Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $6.17.

Immunic Stock Performance

NASDAQ:IMUX opened at $1.25 on Tuesday. Immunic has a 52 week low of $0.51 and a 52 week high of $1.51. The firm’s 50-day simple moving average is $0.90 and its 200 day simple moving average is $0.80. The firm has a market cap of $163.08 million, a price-to-earnings ratio of -1.79 and a beta of 1.46.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Sell-side analysts anticipate that Immunic will post -0.94 EPS for the current year.

Institutional Trading of Immunic

Several large investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP bought a new position in Immunic in the fourth quarter valued at approximately $83,000. Connective Capital Management LLC bought a new stake in Immunic during the fourth quarter worth $161,000. XTX Topco Ltd acquired a new stake in shares of Immunic in the 4th quarter valued at $120,000. Millennium Management LLC boosted its holdings in shares of Immunic by 544.6% in the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after purchasing an additional 2,888,829 shares in the last quarter. Finally, Laurion Capital Management LP increased its stake in shares of Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after purchasing an additional 2,000,000 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.